All News

ILD.colors

Review: Rheumatoid Arthritis–Associated Interstitial Lung Disease

Jack Cush, MD

RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe.

Read Article
RheumNow Podcast square

Moral Distress (3.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.  This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

Read Article
Biologics.new

Spotty Medicare Coverage for Newer Rheumatoid Arthritis Meds

MedPage Today

Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) -- both under Medicare Advantage and in separate Part D plans -- is likely to leave many patients wanting, researchers found.

Read Article
RheumNow Podcast square

Rheumatology Pitfalls (3.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com.

Read Article
guidelines.jpg (keep)

2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Jack Cush, MD

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article
lab%20-rheumatoid-factor-testing.jpg

Pitfalls of autoimmune serologic testing

Jack Cush, MD

Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of  serological autoimmune markers. 

Read Article
What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp
Dr. John Cush RheumNow ( View Tweet)
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and its implications. 🎧 Listen here: https://t.co/QxldIpYQC8 #Rheumatology #Autoimmunity #RNL2026 https://t.co/nz2dbwll14

Links:

Dr. John Cush RheumNow ( View Tweet)
Italian population study of 37996 RA (prevalence 0.54%) pts w/ and 12875 incident cases (incid rate 33.1/100K), there were 1288 deaths/8yrs (MR 21.3/1K), median age=83; SMR 1.28 (1.21 to 1.35), higher <45 yrs (2.15). Leading causes CV (37%), cancer (21%) & infxn (11%) https://t.co/wPx5iqW7Nl
Dr. John Cush RheumNow ( View Tweet)
Time to pregnancy (TTP) in 2 RA cohorts: PARA (n 245, 2002-10) vs PreCARA (n 215, 2011-23), latter Rx by T2T. Median TTP was 251d vs 91d (p<0·0001). Preg w/in 1 yrs was 42% v 77%. 61% PreCARA in remission https://t.co/qIHwXvfzMy https://t.co/1huBKiarhH

Links:

Dr. John Cush RheumNow ( View Tweet)
Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less https://t.co/2ZVyf8neVH
Dr. John Cush RheumNow ( View Tweet)
Advanced Practice Rheum: Rheumatoid & Inflammation Testing In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis. https://t.co/UlBuUhtB01 https://t.co/09OEk1OLs2

Links:

Dr. John Cush RheumNow ( View Tweet)
Incident RA is assoc w/ considerable work loss. 3850 RA pts compared to 4422 same-sex siblings (2006-2020). Work loss began 13 mos before RA Dx & peaked the year after, less in last 10 yrs. Work loss highly skewed; small proportion contributed the most work loss days. https://t.co/splolrEDpe
Dr. John Cush RheumNow ( View Tweet)
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Elena Myasoedova examines mortality trends in RA, exploring whether we are seeing continued decline, delayed impact, or a concerning plateau. 🎧 Listen here: https://t.co/tYS24BNsXw #Rheumatology #RheumatoidArthritis #MedEd https://t.co/GbZV43Cnse

Links:

Dr. John Cush RheumNow ( View Tweet)
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova https://t.co/YoQmrXHZif https://t.co/7v82hHvvZv

Links:

Dr. John Cush RheumNow ( View Tweet)

Prednisone use in Alberta primary care 546 #RA pts - 40% of PCP RA Rx w/ 1 or more prednisone Rx. 41% Rx w/ both Pred + DMARD, w/ 44% on Pred median 124 day before DMARD. 66% continued Pred >1 yr after DMARD initiation. https://t.co/wrxQRP2TWN https://t.co/XxWpjafBsk

Links:

Dr. John Cush RheumNow ( View Tweet)
RA pt on 7.5 mg/d Prednisone need hip replacement. What do you advise re: pred dose before TKR?

Dr. John Cush RheumNow ( View Tweet)

2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management EULAR has updated its RA management recommendations, notably with fewer recommendations (a total of 9, down from 11 in the 2022 version), by merging and removing previous recommendations. https://t.co/7SCIL2Prjw
Dr. John Cush RheumNow ( View Tweet)
https://t.co/4UQlqwujiR 2026 — On Demand Catch the sessions everyone in rheumatology is talking about: • RA advances • Psoriatic arthritis decisions • Spondyloarthritis updates • Autoimmune disease highlights • Vasculitis insights Full recordings + slides available now. https://t.co/QT6NOXakVv

Links:

Dr. John Cush RheumNow ( View Tweet)
Annual fibromyalgia survey (FIRST) in axSpA pts in the DESIR cohort. FM was found in 22% (& assoc w/ less HLA-B27+ & XRay sacroiliitis, equal MRI SI a& ^ CRP. FM/AxSpA had less self-reported Dz activity, QOL, more disability & more likely to Rx w/ TNFi (64% vs 41%), but resp https://t.co/9rkZFUSB2M
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×